Loading...
XNAS
VIR
Market cap760mUSD
Jul 14, Last price  
5.50USD
1D
-2.65%
1Q
-2.14%
IPO
-60.12%
Name

Vir Biotechnology Inc

Chart & Performance

D1W1MN
P/E
P/S
10.25
EPS
Div Yield, %
Shrs. gr., 5y
4.82%
Rev. gr., 5y
153.35%
Revenues
74m
-13.90%
149,000868,000711,00067,245,0001,087,068,0001,580,472,00086,180,00074,205,000
Net income
-522m
L-15.14%
-69,852,000-115,884,000-174,683,000-298,665,000528,584,000515,837,000-615,061,000-521,960,000
CFO
-446m
L-42.69%
-66,381,000-94,096,000-129,632,000-190,941,000-47,589,0001,663,253,000-778,785,000-446,352,000
Earnings
Jul 30, 2025

Profile

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
IPO date
Oct 11, 2019
Employees
576
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
74,205
-13.90%
86,180
-94.55%
1,580,472
45.39%
Cost of revenue
507,344
592,436
620,967
Unusual Expense (Income)
NOPBT
(433,139)
(506,256)
959,505
NOPBT Margin
60.71%
Operating Taxes
(1,145)
(13,077)
238,443
Tax Rate
24.85%
NOPAT
(431,994)
(493,179)
721,062
Net income
(521,960)
-15.14%
(615,061)
-219.24%
515,837
-2.41%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,767
39,440
BB yield
-0.58%
-1.16%
Debt
Debt current
12,867
4,137
Long-term debt
180,278
223,346
247,674
Deferred revenue
1,526
53,207
Other long-term liabilities
38,627
40,218
32,799
Net debt
(1,000,120)
(1,391,471)
(2,174,156)
Cash flow
Cash from operating activities
(446,352)
(778,785)
1,663,253
CAPEX
(7,301)
(21,573)
(68,028)
Cash from investing activities
499,367
164,629
(1,193,461)
Cash from financing activities
4,388
7,480
34,761
FCF
(387,657)
(472,213)
1,180,311
Balance
Cash
990,383
1,522,409
2,402,040
Long term investments
190,015
105,275
23,927
Excess cash
1,176,688
1,623,375
2,346,943
Stockholders' equity
(761,487)
(238,626)
368,128
Invested Capital
2,040,638
1,995,146
1,908,587
ROIC
39.61%
ROCE
42.08%
EV
Common stock shares outstanding
136,247
134,131
134,811
Price
7.34
-27.04%
10.06
-60.25%
25.31
-39.55%
Market cap
1,000,052
-25.89%
1,349,357
-60.45%
3,412,064
-38.93%
EV
(68)
(42,114)
1,237,908
EBITDA
(413,183)
(486,805)
966,288
EV/EBITDA
0.00
0.09
1.28
Interest
183,145
Interest/NOPBT
19.09%